PRESS RELEASE published on 06/13/2025 at 01:25, 9 months 7 days ago Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy FDA Approval Moderna RSV Vaccine Phase 3 Study MRESVIA
BRIEF published on 06/11/2025 at 13:05, 9 months 9 days ago Moderna to Present at Barclays Science Call Series MRNA Technology Presentation Moderna Barclays Investor Event
BRIEF published on 06/11/2025 at 13:05, 9 months 9 days ago Moderna participera à la série d'appels scientifiques de Barclays Presentation Barclays Moderne Événement Pour Les Investisseurs Technologie De L'ARNm
PRESS RELEASE published on 06/11/2025 at 13:00, 9 months 9 days ago Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 Moderna, Inc. announces participation in Barclays Speaking the Science Call Series on June 16th at 10:00am ET. Webcast available on Moderna's website Webcast MRNA Medicine Moderna Barclays Investor Event
BRIEF published on 05/31/2025 at 06:21, 9 months 20 days ago Moderna's mNEXSPIKE COVID-19 Vaccine Secures FDA Approval FDA Approval COVID-19 Vaccine Clinical Trial Moderna MNEXSPIKE
BRIEF published on 05/31/2025 at 06:21, 9 months 20 days ago Le vaccin mNEXSPIKE de Moderna contre la COVID-19 obtient l'approbation de la FDA Essai Clinique Approbation De La FDA Moderne Vaccin Contre Le Covid-19 MNEXSPIKE
PRESS RELEASE published on 05/31/2025 at 06:16, 9 months 20 days ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna's mNEXSPIKE, a new COVID-19 vaccine, receives FDA approval for high-risk age groups. The vaccine shows higher efficacy compared to the original mRNA-1273. Safety profile similar to Spikevax FDA Approval COVID-19 Vaccine Moderna Efficacy MNEXSPIKE
BRIEF published on 05/29/2025 at 00:05, 9 months 22 days ago Moderna Reports Progress and Setback in Avian Flu Vaccine Program Moderna Vaccine Development Phase 1/2 Study H5 Avian Flu MRNA-1018
BRIEF published on 05/29/2025 at 00:05, 9 months 22 days ago Moderna fait état de progrès et de revers dans son programme de vaccination contre la grippe aviaire Développement De Vaccins Moderne Étude De Phase 1/2 Grippe Aviaire H5 ARNm-1018
PRESS RELEASE published on 05/29/2025 at 00:00, 9 months 22 days ago Moderna Announces Update on Investigational Pandemic Influenza Program Moderna's Phase 1/2 H5 avian flu vaccine study shows positive interim results with robust immune response. HHS terminates late-stage development award Moderna Phase 1/2 Study Avian Flu Vaccine H5 Subtype HHS Termination
Published on 03/20/2026 at 13:30, 8 hours 8 minutes ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 9 hours 8 minutes ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/20/2026 at 12:00, 9 hours 38 minutes ago Organto Foods Inc. Announces Marketing Engagements with VSA Capital Limited and Venture Liquidity Partner Ltd.
Published on 03/20/2026 at 21:05, 33 minutes ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 33 minutes ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 38 minutes ago BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 1 hour 33 minutes ago INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action
Published on 03/20/2026 at 19:06, 2 hours 32 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/20/2026 at 19:00, 2 hours 38 minutes ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 hours 38 minutes ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 3 hours 23 minutes ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 3 hours 23 minutes ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
